Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Recent & Breaking News (GREY:ATBPF)

Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update

Business Wire November 28, 2017

Antibe Therapeutics Announces Key US Distribution Partnership for Its Subsidiary, Citagenix

Business Wire October 26, 2017

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Business Wire October 20, 2017

Antibe Therapeutics Inc., Safe Pain and Inflammation Medicine, CEO Clip Video

Newsfile September 13, 2017

Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead Drug, ATB-346

Business Wire September 8, 2017

Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results

Business Wire August 29, 2017

Antibe Therapeutics Inc. Announces Closing of Public Offering

Business Wire August 18, 2017

Antibe Therapeutics Receives Approval to Initiate Phase 2 Gastrointestinal Endoscopy Clinical Trial

Business Wire August 2, 2017

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Business Wire July 28, 2017

Antibe Therapeutics Inc. Announces Closing of Public Offering

Business Wire June 21, 2017

Antibe Therapeutics Inc. Announces Filing of Final Short Form Prospectus

Business Wire June 15, 2017

Antibe Therapeutics Inc. Announces Pricing of Offering

Business Wire May 26, 2017

IIROC Trading Resumption - ATE

Canada NewsWire May 25, 2017

IIROC Trade Resumption - Antibe Therapeutics Inc.

Newsfile May 25, 2017

Antibe Therapeutics Inc. Announces Proposed Offering of Units

Business Wire May 24, 2017

IIROC Trading Halt - ATE

Canada NewsWire May 24, 2017

IIROC Trade Halt - Antibe Therapeutics Inc.

Newsfile May 24, 2017

Antibe Therapeutics Engages Topstone Research and Appoints Dr Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346

Business Wire May 12, 2017

Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic

Business Wire April 26, 2017

Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 24, 2017